Saiba Animal Health’s innovative technology platform uses a first-of-its-kind, patented therapeutic vaccine platform, designed to create an immune response, targeting chronic diseases such as allergy, inflammation and pain. The therapeutic vaccines incorporate virus-like particles (VLP) to induce the animal’s immune system. They produce neutralizing antibodies against the animal’s own disease-causing proteins. This approach may result in a longer duration of action, better treatment outcomes, and increased pet owner convenience and compliance.
Founded in 2013 as a spin-off from the University of Zurich, the Freienbach (Schwyz)-based startup has now been acquired by Boehringer Ingelheim, following several development and licensing collaborations. Together they advanced multiple species-specific product candidates, based on Saiba Animal Health’s technology platform, aiming to improve the management of chronic diseases in companion animals.
“Our pets live longer which creates different needs for their medical care, and often without good existing treatment options”, said Eric Haaksma, Head of Global Innovation, Animal Health at Boehringer Ingelheim. “As a research-driven company, we are very excited about the potential of Saiba Animal Health’s groundbreaking technology platform, which could result in a more specific and longer-lasting therapeutic response to chronic diseases in companion animals than current approaches.”
Dr. Gary T. Jennings, CEO of Saiba Animal Health, said: “We are thrilled that our long-term partnership with Boehringer Ingelheim has evolved to this agreement. Joining forces will pave the way for a whole new class of therapeutic medicines for pets, with a true impact on the lives of animals and their owners.”
(Press release/RAN)